MX2023005171A - Composiciones y metodos para tratamiento de cancer solido. - Google Patents

Composiciones y metodos para tratamiento de cancer solido.

Info

Publication number
MX2023005171A
MX2023005171A MX2023005171A MX2023005171A MX2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A MX 2023005171 A MX2023005171 A MX 2023005171A
Authority
MX
Mexico
Prior art keywords
compositions
methods
solid cancer
treating solid
treating
Prior art date
Application number
MX2023005171A
Other languages
English (en)
Inventor
C Allen Robert
Jr Jackson T Stephens
Original Assignee
Exoxemis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exoxemis Inc filed Critical Exoxemis Inc
Publication of MX2023005171A publication Critical patent/MX2023005171A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/0101—Chloride peroxidase (1.11.1.10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/02—Oxidoreductases acting on a peroxide as acceptor (1.11) with H2O2 as acceptor, one oxygen atom of which is incorporated into the product (1.11.2)
    • C12Y111/02002—Myeloperoxidase (1.11.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan composiciones y métodos para tratar el cáncer sólido. Específicamente, la descripción proporciona composiciones que comprenden haloperoxidasas y métodos que comprenden la administración de tales composiciones para tratar el cáncer sólido.
MX2023005171A 2020-11-11 2021-10-01 Composiciones y metodos para tratamiento de cancer solido. MX2023005171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112447P 2020-11-11 2020-11-11
PCT/US2021/053155 WO2022103515A1 (en) 2020-11-11 2021-10-01 Compositions and methods for treating solid cancer

Publications (1)

Publication Number Publication Date
MX2023005171A true MX2023005171A (es) 2023-06-26

Family

ID=81601629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005171A MX2023005171A (es) 2020-11-11 2021-10-01 Composiciones y metodos para tratamiento de cancer solido.

Country Status (10)

Country Link
US (1) US20230398190A1 (es)
EP (1) EP4243835A1 (es)
JP (1) JP2023548406A (es)
KR (1) KR20230106646A (es)
CN (1) CN116710121A (es)
AU (1) AU2021379542A1 (es)
CA (1) CA3196357A1 (es)
IL (1) IL302683A (es)
MX (1) MX2023005171A (es)
WO (1) WO2022103515A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023200842A1 (en) * 2022-04-13 2023-10-19 Exoxemis, Inc. Compositions and methods for treating solid cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103525A2 (en) * 2006-03-09 2007-09-13 Glanbia Nutritionals (Ireland) Limited Cationic whey protein composition
CA2839747A1 (en) * 2011-07-11 2013-01-17 Exoxemis, Inc. Eosinophil peroxidase compositions and methods of their use
US10076556B2 (en) * 2015-01-29 2018-09-18 Oxyrase, Inc. Methods for inhibiting tumor growth

Also Published As

Publication number Publication date
AU2021379542A1 (en) 2023-06-08
WO2022103515A1 (en) 2022-05-19
US20230398190A1 (en) 2023-12-14
CN116710121A (zh) 2023-09-05
IL302683A (en) 2023-07-01
KR20230106646A (ko) 2023-07-13
JP2023548406A (ja) 2023-11-16
CA3196357A1 (en) 2022-05-19
EP4243835A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019012038A (es) Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
NZ742787A (en) Compositions comprising bacterial strains
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2018067512A8 (en) SPIROCYCLIC COMPOUNDS
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP4378535A3 (en) Antibiotic formulations for lower back pain
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2022008099A (es) Tratamiento para el cancer con inhibidores de cdk12/13.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
WO2018208954A3 (en) Peptidomimetic macrocycles and uses thereof
MY200161A (en) Bacteria for targeting tumors and treating cancer
MX2022002337A (es) Polipéptidos de tff2 modificados.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
MX2023005171A (es) Composiciones y metodos para tratamiento de cancer solido.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
WO2018183692A8 (en) VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
ZA202301035B (en) Dual car-t cells